NCT06699966Not yet recruitingPhase 4
Stony Brook Medicine Anti-Inflammatory Trial
Source: ClinicalTrials.gov · Last updated 23 Apr 2026
Brief summary (registry, in English)
This is an experimental study designed to measure the effect of celecoxib or minocycline on depressive symptoms in unipolar and bipolar depression. Participants will be equally randomized to either celecoxib or minocycline. All participants will complete a battery of clinical and psychological assessments prior to treatment assignment, and again after treatment completion, to assess any changes or improvements in depression.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 42 (estimated)
- First submitted
- 19 Nov 2024
- Start date
- Jun 2027
- Primary completion date
- Jun 2031
- Lead sponsor
- Stony Brook University
- Diseases
- Depression
- NCT number
- NCT06699966
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 42
- From Jun 2027 to the primary completion date, Jun 2031
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Hypersensitivity to celecoxib, minocycline, tetracyclines, sulfonamides, aspirin, other NSAIDs, or any component of the formulation; previous asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs
- Use of herbs, drugs, or medications with anti-inflammatory or immunomodulatory properties (within 5 half-lives of starting celecoxib or minocycline treatment)
- Unlikely to tolerate medication washout or the medication-free period following washout.
- Electroconvulsive therapy (ECT) within 1 month
- High potential for excessive drug/alcohol use during the treatment period (excluding nicotine or cannabis)
- Need for medications that control mania.
Other illness
- History of myocardial infarction or current cardiac condition
- Heptic impairment, heart failure, severe renal impairment, recent GI bleed, history of peptic ulcer disease, anemia or any other contraindication for celecoxib or minocycline
- Significant active physical illness or neurological deficit that may affect brain functioning.
Lab values
- Currently taking medications that interact with celecoxib (digoxin, antihypertensives, diuretics, anticoagulant or anti-platelet treatment, including aspirin), or minocycline (isotretinoin, ergot alkaloids) without providing physicians approval
Other
- Poor CYP2C9 metabolizer
- Participant considered at significant risk for suicide.
- If participant is currently pregnant, breastfeeding, or planning to conceive during the course of study participation.
Who the study is looking for
- Current consent form signed
- Capacity to give informed consent
- Age range 18-65 (inclusive)
- Diagnosis of MDD or bipolar depression and currently in a major depressive episode
- Score of at least 29 on the MADRS (at least moderate depression)
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.